Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) shares dropped 6.7% during trading on Wednesday . The stock traded as low as $9.46 and last traded at $9.52. Approximately 562,263 shares traded hands during trading, a decline of 40% from the average daily volume of 936,675 shares. The stock had previously closed at $10.20.
Analyst Upgrades and Downgrades
NAGE has been the subject of several research analyst reports. Canaccord Genuity Group boosted their price objective on shares of Niagen Bioscience from $13.00 to $16.00 and gave the company a "buy" rating in a research report on Tuesday, June 10th. HC Wainwright upped their price target on shares of Niagen Bioscience from $11.00 to $12.00 and gave the stock a "buy" rating in a report on Monday, August 11th. Wall Street Zen downgraded Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a report on Tuesday, September 9th. Finally, Roth Capital restated a "buy" rating and set a $23.00 price objective (up previously from $10.00) on shares of Niagen Bioscience in a research report on Friday, June 6th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $13.42.
Get Our Latest Analysis on Niagen Bioscience
Niagen Bioscience Trading Down 6.6%
The stock has a market capitalization of $760.02 million, a P/E ratio of 45.38 and a beta of 2.21. The company's fifty day simple moving average is $9.76 and its 200 day simple moving average is $9.28.
Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.04 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%. The company had revenue of $31.12 million for the quarter, compared to analysts' expectations of $28.55 million.
Institutional Trading of Niagen Bioscience
Hedge funds and other institutional investors have recently modified their holdings of the company. State of Wyoming bought a new position in Niagen Bioscience during the fourth quarter valued at $39,000. ProShare Advisors LLC purchased a new position in shares of Niagen Bioscience in the 4th quarter worth approximately $74,000. Deutsche Bank AG grew its position in shares of Niagen Bioscience by 1,733.4% in the 4th quarter. Deutsche Bank AG now owns 26,878 shares of the company's stock worth $143,000 after buying an additional 25,412 shares during the last quarter. Bank of America Corp DE grew its position in shares of Niagen Bioscience by 89.5% in the 4th quarter. Bank of America Corp DE now owns 52,144 shares of the company's stock worth $277,000 after buying an additional 24,622 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in Niagen Bioscience during the 4th quarter worth approximately $555,000. 15.41% of the stock is owned by hedge funds and other institutional investors.
About Niagen Bioscience
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
